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Abstract 
Dendritic cells (DCs) are the professional APCs of the immune system, enabling T cells to perceive 
and respond appropriately to potentially dangerous microbes, while also being able to maintain T 
cell tolerance toward self. In part, such tolerance can be determined by IL-10 released from certain 
types of regulatory T cells. IL-10 has previously been shown to render DCs unable to activate T cells 
and it has been assumed that this process represents a general block in maturation. Using serial 
analysis of gene expression, we show that IL-10 pretreatment of murine bone marrow-derived DCs 
alone causes significant changes in gene expression. Furthermore, these cells retain the ability to 
respond to Toll-like receptor agonists, but in a manner skewed toward the selective induction of 
mediators known to enhance local inflammation and innate immunity, among which we highlight a 
novel CXCR2 ligand, DC inflammatory protein-1. These data suggest that, while the presence of a 
protolerogenic and purportedly anti-inflammatory agent such as IL-10 precludes DCs from acquiring 
their potential as initiators of adaptive immunity, their ability to act as initiators of innate immunity 
in response to Toll-like receptor signaling is enhanced.  
Introduction 
Dendritic cells (DCs)3 are not only recognized as important initiators of immunity, characteristically 
unique in their ability to stimulate naive T cells, but also as key determinants of the type of immunity 
initiated. They have variously been termed “sensors of infection” and “plastic”, reflecting their ability 
to convey context of Ag encounter to direct adaptive immunity (1, 2), while “immature” DCs have 
been implicated in mediating peripheral tolerance (3, 4). Under experimental conditions, a number 
of agents have been reported to modulate the immunostimulatory potential of DCs (3, 5). 
Modulation by IL-10 results in DCs that are no longer capable of presenting Ag for immunity, but 
induce Ag-specific anergy in both CD4+ and CD8+ T cells (5, 6, 7, 8).  
Classic maturation of DCs in response to inflammatory stimuli involves extensive reprogramming, 
manifest as a temporally coordinated cascade, facilitating the conversion of cells specialized for high 
Ag uptake, but exhibiting poor T cell stimulatory properties, to cells that no longer sample Ag, but 
are highly efficient T cell stimulators (2, 9). This conversion is accompanied by changes in migration 
priorities, initially facilitating recruitment and then release of DCs from the site of inflammation, and 
subsequently homing of Ag-bearing mature DCs to lymphoid tissue. Inflammatory mediators 
produced early in the response at the site of activation are replaced at later time-points by 
mediators promoting DC:T cell interactions (10). IL-10 does not effect the capacity of immature DCs 
for Ag uptake, but does prevent the chemokine receptor switch required for maturation-induced 
lymphoid homing, and alters Ag presentation, preventing up-regulation of MHC class II, as well as 
costimulatory and adhesion molecules, impeding acquisition of T cell stimulatory capacity (5, 7, 11, 
12). Given these observations, it has been suggested that IL-10 mediates its immunosuppressive 
effects on DCs by blocking normal maturation (7, 11). An alternative proposal is that DCs are actively 
“conditioned” by IL-10 to modify the quality of any subsequent response to stimuli (13).  
In this study, we have used serial analysis of gene expression (SAGE) (14) to identify genes regulated 
following LPS-induced maturation of murine bone marrow-derived DCs (BMDCs), and to investigate 
changes in this regulation effected by pretreating the cells with IL-10. This analysis has facilitated the 
identification and cloning of a novel LPS-induced chemokine, the functional characteristics and 
induction of which are consistent with activity during the early proinflammatory phase of DC 
maturation. Pretreatment with IL-10 did not hinder the induction of this, or other related 
chemokines. SAGE library comparisons indicate that IL-10 conditions BMDCs to acquire a state from 
which, although compromised in their ability to present Ag for immunity, they remain competent to 
generate innate immune responses to microbial danger signals.  
Materials and Methods 
Cells 
BMDCs were generated using an adaptation of Inaba et al. (15). Briefly, CBA/Ca marrow was sieved 
through a 70-μm nylon mesh in R10 medium (RPMI 1640, 10% FCS, 2 mM l-glutamine, 50 U/ml 
penicillin, 50 μg/ml streptomycin, 5 × 10−5 M, 2-ΜΕ), red cells lysed using ammonium chloride, and 
cells plated at 7.5 × 106 per 10 cm plate (Corning, Corning, NY), supplemented with ∼25 ng/ml 
murine recombinant GM-CSF, supplied as culture supernatant. Medium was replaced on days 3 and 
6 and BMDCs harvested on day 7 by gentle pipetting. For maturation, 1 μg/ml LPS (Sigma-Aldrich, St. 
Louis, MO), 2 μM 5′-TCCATGACGTTCCTGATGCT-3′, CpG, or 5′-TCCATGAGCTTCCTGATGCT-3′, GpC 
(control) were added late on day 6 and cells harvested at the required time-points. IL-10 was added 
at 20 ng/ml (R&D Systems, Minneapolis, MN) from day 6 and cells harvested on day 9, with or 
without inclusion of 1 μg/ml LPS for the final 18–20 h. Control BMDC were also harvested on day 9. 
Surface phenotype was assessed by flow cytometry using mAbs; N418 (CD11c), 17-3-3S (H-2Ek), FGK-
45 (CD40), YN1.1 (CD54), 1G10 (CD80), 2D10 (CD86), and 28-8-6S (H-2Kk)(BD PharMingen, San Diego, 
CA). For allogeneic MLR, mitomycin C-treated CBA/Ca BMDCs were titrated into cultures of nylon 
wool-purified C57BL/10 splenic T cells, incubated for 3 days, and pulsed with 3H-TdR 24 h before 
harvesting. Capacity to process and present soluble Ag was assessed as the ability to stimulate IL-2 
release from the T cell hybridoma 2G7.1, specific for hen egg-white lysozyme1–18, in the context of H-
2Ek (16).  
Bone marrow macrophages were from 129/1CR mice (17), peritoneal exudates from BALB/c mice, 
with or without 1 ml Biogel P-100 polyacrylamide beads, 100–200 mesh (Bio-Rad, Hercules, CA) 
injected i.p. 4–5 days before lavage. Resident cells were plated at 1 × 106 per well in six-well plates, 
elicited cells at 1 × 107 per well in 9 cm dishes in Optimem (Invitrogen, San Diego, CA), supplemented 
with 2 mM l-glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, and cultured for 24 h with or 
without 1 μg/ml LPS, washed with PBS, and directly lysed in the culture dish for RNA isolation.  
SAGE 
Libraries were generated, using the anchor enzyme NlaIII (New England Biolabs, Beverly, MA), the 
tagging enzyme BsmFI (New England Biolabs) and biotinylated SAGE primers (14, 18). Poly(A)+ mRNA 
was isolated from ∼100 μg total RNA, and cDNA generated using a Roche Diagnostics kit (Basel, 
Switzerland). Concatenated ditags were cloned to the SphI site of pGEM3Zf (Promega, Madison, WI). 
Amplified inserts were precipitated using polyethylene glycol, sequenced using the DYEnamic ET dye 
terminator kit (Amersham Pharmacia Biotech, Piscataway, NJ) and analyzed on a MegaBACE1000 
capillary sequencer (Amersham Pharmacia Biotech). SAGE 3.04 beta software (K. W. Kinzler, Johns 
Hopkins Oncology Center, Baltimore, MD) was used to extract tag sequences. Automated 
hierarchical assignments were generated using Unigene full mapping files and a custom search 
algorithm, with tags matching 9 of 10 bases of any other tag occurring at >10-fold frequency within 
the entire dataset or any linker excluded, and custom software was used for statistical analysis (19).  
RACE 
Total RNA from CBA/Ca LPS-treated BMDCs was reverse transcribed using a SMART cDNA synthesis 
kit (BD Biosciences Clontech, Palo Alto, CA), primed using 5′-GACTCGAGTTGACATCGAGG(T)20V-3′. 5′-
GACTCGAGTTGACATCGAGG-3′ and 5′-CATGAAATATCAAC-3′ were used for 3′ RACE, (30 s at 94°C, 30 
s at 39°C, 30 s at 72 C) for 35 cycles. 5′RACE was performed using the SMART II CDS primer, 5′-
AAGCAGTGGTAACAACGCAGAGT-3′ and a series of nested or individual, reverse primers; 5′-
TTAAACTTCTCCATTCTAAGACAT-3′ nested with 5′-AGGCATTAAATAGTCACTGTGCC-3′; 5′-
AGACACCGTTGGGATGGATCGCT-3′, nested with 5′-TCAGCTGGACTTGCCGCTCTTCA-3′; and 5′-
GTCAAGCTCTGGATGGTCTCAAAA-3′. Amplifications were performed using Pfu turbo DNA 
polymerase (Stratagene, La Jolla, CA), “A-tailed” using Biotaq DNA polymerase (Bioline, London, 
U.K.) and cloned to pGEM-T Easy (Promega). Inserts were identified by colony PCR, polyethylene 
glycol precipitated, and sequenced to generate a full-length cDNA contig.  
Genomic cloning 
A mouse embryonic stem cell (129/Sv × 129/Sv-CP) genomic λ library was screened using an ∼840 
bp cDNA probe, amplified using primers 5′-GTGCTGCACTGGTCCTGCT-3′ and 5′-
AGGCATTAAATAGTCACTGTGCC-3′, and labeled using Ready-To-Go DNA labeling beads (Amersham 
Pharmacia Biotech). All hybridizations were performed in 50% formamide, 6× SSC, 10× Denhardts, 
0.5% SDS, in the presence of 100 μg/ml denatured herring sperm DNA (Sigma-Aldrich), rotating at 
42°C in a Techne Hybridizer HB-1D (Techne Laboratories, Cambridge, UK). Membranes were washed 
to 0.2 × SSC, 0.1% SDS at 65°C. Three rounds of screening yielded nine clones. An ∼7 kb XbaI 
fragment was subcloned to pGEM3zf (Promega) and sequenced using extending primers.  
Real-time PCR 
DNase I-treated RNA, prepared using the SV total RNA isolation kit (Promega), was reverse 
transcribed using Stratagene’s ProSTAR first strand RT-PCR kit. DC inflammatory protein (DCIP)-1 
primers, 5′-GGAAAGGAGGAAGCCCCTC-3′ and 5′-AACAAGCAGGTAAAGACACATCCA-3′, and probe, 
5′FAM-ACCTGCATTCTAAATCAGAGAAAAGCGATCCA-3′, macrophage inflammatory protein (MIP)-2 
primers, 5′-ACCAAAGAGAAAGAAAAAAACAAACAG-3′ and 5′-CTCAGACAGCGAGGCACATC-3′ and 
probe 5′FAM-ACCCGGGAAGCCTGGATCGTACC-3′, CCR7 primers, 5′-GCTGCGTCAACCCTTTCTTG-3′ and 
5′-ACCGACGCGTTCCGTACAT-3′ and probe 5′FAM-TTCATCGGCGTCAAGTTCCGC-3′, CCL5 primers, 5′-
CATATGGCTCGGACACCACTC-3′ and 5′-CGACTGCAAGATTGGAGCAC-3′ and probe 5′FAM-
CTGCTGCTTTGCCTACCTCTCCCTCG-3′ and HPRT primers, 5′-GACCGGTCCCGTCATGC-3′ and 5′-
TCATAACCTGGTTCATCATCGC-3′ and probe, 5′VIC-ACCCGCAGTCCCAGCGTCGTG-3′, were designed 
using Primer Express software (Applied Biosystems, Foster City, CA). Probes (Applied Biosystems) 
were labeled with a 5′ flurogenic dye and a 3′ quencher (TAMRA). Primers (MWG Biotech, Ebersburg, 
Germany) were HPSF purified. Multiplex reactions were performed using TaqMan Universal PCR 
MasterMix (Applied Biosystems) and a Prism 7700 sequence detector system (Applied Biosystems). 
Standard curves generated from LPS-treated BMDC cDNA were used to calibrate the threshold cycle 
value on each 96-well plate. Samples, analyzed in triplicate, are represented as a mean normalized 
ratio to HPRT (mean (test/HPRT) × 100). Limits of detection were defined as the mean normalized 
ratio at 40 cycles and used to position the axes of data plots.  
N-terminal sequence analysis of DCIP-1-Fc fusion protein 
DCIP-1, amplified using primers 5′-CTTCGCACAAGCTTCCGCGCTCCA-3′ and 5′-
TTTCCCGGGATCCGAGGACTTGCGG-3′ (introducing HindIII and BamHI sites, underlined), was cloned 
in-frame with human IgG1-Fc, in pCDM8 (20). Supernatants were harvested 72 h after DEAE-dextran 
transfection of COS-7 cells and fusion protein purified by adsorption to protein A-Sepharose beads. 
N-terminal protein sequence analysis was performed by M. A. C. Willis, (Department of 
Biochemistry, Oxford University, Oxford, U.K.).  
Synthetic chemokines 
Mature DCIP-1 (Ala28-Ser100) was chemically synthesized using solid-phase F-moc chemistry on a 
433A automated peptide synthesizer (Applied Biosystems). Purification and folding were essentially 
as described (21). Purity and molecular integrity of the folded protein were confirmed by analytical 
HPLC and electron-spray mass spectrometry (>95% purity, experimentally determined m.w., 7910.1). 
Murine IP-10, also produced synthetically, exhibited the same specific activity in binding and 
functional assays as commercial IP-10. KC and MIP-2 were purchased from R&D Systems.  
Generation of murine CXCR2 transfectants 
Murine CXCR2 was amplified from C57BL/6J genomic DNA using 5′-
GCAGGATCCAGTTTACCTCAAAGATGGGAGAGTTC-3′ and 5′-
ACAGAATTCAGAGGGTAGTAGAGGTGTTTGCTGA-3′ (introducing BamHI and EcoR1 cloning sites, 
underlined, and removing an EcoRI site, double underlined), and cloned to pcDNA3.1 (Invitrogen), 
modified to carry the elongation factor-1α promoter. Stable RBL-1 transfectants were generated by 
electroporation, with single cell clones selected by chemotaxis to human growth-related oncogene 
(GRO)α, MIP-2, DCIP-1, and KC, and maintained in 0.8 mg/ml G418.  
Chemotaxis assays 
Assays were performed using 24-well Biocoat Transwell culture inserts (Costar, Cambridge, MA; 3 
μm) (22). For RBL-1 stable transfectant clones, naked inserts were used. For human neutrophils the 
inserts were coated with 2 × 105 ECV304 cells. Neutrophil chemotaxis was performed using the 
granulocyte fraction isolated from fresh blood by percoll density centrifugation (22). Briefly, 1 × 106 
cells in 100 μl of chemotaxis media (RPMI 1640, 0.5% BSA) were dispensed in the upper transwell 
and 600 μl of chemotaxis media with or without chemokine placed in the bottom well. Incubation 
was at 37°C for 5 h for cell transfectants, or 30–60 min for human neutrophils. Cells that migrated to 
the bottom well were counted using FACS, with numbers expressed as relative FACS counts, 
obtained by acquiring events for a set time of 30 s.  
Peritoneal recruitment assay 
Lavages were performed 90 min after 200 μl i.p. injections of 5 μg/ml chemokine in PBS or PBS 
alone. Cytospins, 5 × 105 cells/slide, were stained with Wright-Giemsa stain (Fisher Diagnostics, 
Pittsburgh, PA). The percentage of macrophages, mononuclear cells, and neutrophils were 
determined by counting eight random high power fields (×40 magnification; total area, 0.5 mm2) and 
related to total numbers in the lavage.  
Results 
SAGE comparison of untreated and LPS-treated BMDCs 
Murine BMDCs cultured for 7 days in GM-CSF exhibit surface and functional phenotypes 
characteristic of immature DCs, while inclusion of LPS for the final 18–20 h generates cells with 
characteristics typical of mature DCs; increased surface expression of MHC class II and costimulatory 
molecules, diminished capacity to take up and present new Ag, and enhanced capacity to stimulate 
primary T cells in an allogeneic MLR (Fig. 1⇓) (9). SAGE libraries were generated from both untreated 
(21,789 tags) and LPS-treated (13,085 tags) BMDC (GEO, GSM3833, and GSM3832), with surface 
phenotype used to verify the degree of homogeneity (>90% CD11c+) and relative states of 
maturation of each starting cell population. Statistical comparison of tag frequencies revealed 74 
tags differentially up-regulated in the untreated population and 28 tags up-regulated in the LPS-
treated population (Fig. 2⇓).  
 View larger version: 
FIGURE 1.  
Characterization of BMDCs. A, Surface phenotype of untreated (filled histograms) and LPS-treated 
(open histograms) BMDCs, determined by flow cytometry. Broken lines represent background 
staining obtained using irrelevant species- and isotype-matched control Abs. B, Processing and 
presentation of soluble HEL by immature (○) and LPS-treated (▴) BMDCs, assessed by their ability to 
stimulate IL-2 release from the T cell hybridoma 2G7.1, determined by ELISA. To control for the 
effects of endocytosis, immature BMDCs fixed with paraformaldehyde were included (▪). C, Relative 
capacity of immature (○) and LPS-treated (▴) BMDCs to stimulate T cell proliferation, determined 
using allogeneic MLR.  
 
View larger version: 
FIGURE 2.  
Scatter-plot comparison of untreated and LPS-treated BMDC SAGE libraries. Individual tag 
frequencies normalized to 104 tags are plotted on logarithmic scales. Tags lying outside the marked 
area are differentially expressed (95% confidence of >1.5-fold difference) and represented as •. For 
the purpose of clarity of presentation ∼1000 nondifferential tags, mostly mapping to house-keeping 
and ribosomal protein genes, were removed from the analysis. Annotated transcripts were identified 
using the SAGE tags; MHC-IH2K GATTGAGAAT (2.3 vs 33.6), β-2M (beta2) TTTTCAAAAA (0.5 vs 27.5), 
H2-IAα GAAGAAGTGG (39.9 vs 20.6), H2-IEβ TCCTGCTTGG (70.2 vs 16.8), H2-IAβ GCACTATTGT (37.6 
vs 7.6), cystatin C CCTTGCTCAA (58.7 vs 97.1), Ii, CD74 GTTCAAGTGA (90.4 vs 80.2), cathepsin S 
ATAGCCCCAA (8.3 vs 1.5), RAMP4 TAATTTACCT (0 vs 5.4), lysozyme TGTCAGTCTG (31.2 vs 6.1), CCL5 
AAGATCTCTG (0.5 vs 63.4), CCL17 GTTTCAACAT (3.7 vs 32.1), CCL21 GCGCCCTTCC (0 vs 3.8), CCL22 
TCCTGAAGGT (1.4 vs 40.5), CXCL16 CTGTCTTGAG (0 vs 9.9), CCR1 GGCCCAATAA (7.8 vs 0), CCR5 
CAGTTTCGGA (6 vs 0.8), CCR7 TTCTGCTTTT (0.9 vs 32.9), complement factor B CAAAGGAGAT (0 vs 
13), properdin AACTGAGGGG (17.9 vs 3.1), with tag frequencies indicated in brackets (untreated vs 
LPS-matured).  
The relative distribution of gene-tags corresponding to transcripts associated with well-documented 
features of DC maturation provided validation for the integrity of the libraries (Fig. 2⇑). SAGE tags 
corresponding to MHC class I α and β2 microglobulin (β-2M) chains were increased, 14.6- and 55-fold 
respectively, in the LPS-matured library, consistent with delayed neo-synthesis (23), while MHC class 
II α- and β-chain tags were relatively low, consistent with synthesis as a rapid transient burst, 
peaking as early as 1 h post stimulation, and having resolved by the 18–20 h SAGE time-point (24). 
The invariant chain (Ii, CD74) tag was abundant in both libraries. Although this tag cannot distinguish 
between Ii-p31 and Ii-p41 isoforms, the ratio of these isoforms has previously been reported to be 
unchanged at the protein level on DC maturation (25). The tag for cystatin C, an endogenous 
inhibitor of the Ii processing enzyme cathepsin S, was also abundant in both libraries. Although 
implicated in retention of MHC class II molecules in immature DCs (25), increased cathepsin S 
activity on maturation has been shown to be independent of changes in cystatin C expression or 
subcellular distribution (26). The tag for ribosomal-associated membrane protein 4 (RAMP4) 
occurred at a frequency of 5.3 per 104 in the mature library. Although not differential by statistical 
criteria at the current library sizes, this tag was not represented in the immature library. RAMP4 has 
been reported to interact with nascent Ii, controlling glycosylation and transport into the 
endoplasmic reticulum, and possibly impacting on the cell’s capacity to present Ag (27).  
Expected changes in migratory properties of maturing DCs were also reflected in the SAGE data (Fig. 
2⇑) (10). Tags for chemokine receptors CCR1 and CCR5, which mediate recruitment and retention of 
DCs at inflamed sites, were differentially represented in the immature library, while the tag for 
CCR7, which mediates homing to lymphoid organs in response to the cognate ligands CCL19 and 
CCL21, was increased in the LPS-matured library. Tags for CCL21, which also attracts CCR7-bearing 
naive T cells, and for CCL17, CCL22, and CXCL16, which attract recently activated and memory T cells 
expressing the cognate receptors CCR4 and CXCR6, were differentially expressed in the LPS-matured 
library, consistent with promoting DC:T cell interactions required for recruitment of an appropriate 
adaptive effector response.  
SAGE reveals an unassigned tag restricted to LPS-matured BMDCs 
SAGE tag, AAATATCAAC, occurred at a frequency of 12.2 per 104 in the LPS-treated library, but was 
not represented in the untreated library (Fig. 2⇑). Furthermore, it was not represented in SAGE 
libraries derived from fibroblasts (www.sagenet.org), an embryonic stem cell line (GSM3829), 
various T cells (GSM3677–79, GSM3681–86), and lymph nodes (GSM3680 and GSM3687). Using the 
SAGEmap tag-to-gene mapping resource (28), which uses UniGene cluster information in 
conjunction with GenBank information, it was not possible to identify any gene-match for this tag.  
RACE extension of SAGE tag AAATATCAAC reveals a novel ELR+, CXC chemokine  
The SAGE tag-derived primer 5′-CATGAAATATCAAC-3′, generated a 234 bp 3′ RACE product, 
containing a typical polyadenylation sequence, AATAAA, located 12 bp upstream of a putative poly-A 
tail. Extension of this sequence using 5′RACE provided an ∼1 kb full-length cDNA sequence 
(AY311403), encoding a previously undescribed ELR+, CXC chemokine. The extent of the 27 aa leader 
peptide sequence was confirmed by sequence analysis. The chemokine is ∼82% identical to MIP-2 
and we have termed it dendritic cell inflammatory protein-1, DCIP-1. (A single polymorphic amino 
acid substitution, E49 to K49, was detected in the Mus spretus strain, AY311405).  
In rodents, the murine KC and MIP-2, and the rat cytokine-induced neutrophil chemoattractant 
(CINC) proteins, are the closest relatives of the human GRO proteins, and these molecules have 
previously been assigned as a subgroup of ELR+, CXC chemokines (29). By homology DCIP-1 
represents a new member of this subgroup and likely represents the previously undescribed murine 
homologue of CINC-2 (∼80% identical); no mRNA species equivalent to the 3′ alternatively spliced β 
form of CINC2 (30) has yet been identified. The gene (AY311404) is organized as 4 exons and 3 
introns, as are genes encoding other chemokines of this subgroup. Sequence overlap with the 
genomic clone AF349465, encompassing three other CXC chemokine genes CXCL5, CXCL7, and 
CXCL4, positioned the DCIP-1 gene within the MIP-2 and KC containing proinflammatory gene cluster 
on murine chromosome 5, ∼12.4 kb downstream of CXCL4. A TATA-box and a putative NF-κB 
binding site, positioned −32 to −27 and −75 to −66, respectively, from the transcription start site 
(assigned by 5′RACE), are both highly conserved within promoters of other members of this 
subgroup, with the NF-κB binding site important for the induction of these genes in response to 
inflammatory stimuli, including LPS (31, 32, 33, 34).  
The DCIP-1 gene has now been computationally annotated on the mouse genome, XM_284097, 
although this entry is truncated compared with the sequence described here and does not include 
the SAGE tag sequence.  
DCIP-1 interacts with CXCR2 and mediates neutrophil chemotaxis 
DCIP-1-mediated chemotaxis of murine CXCR2 transfected RBL-1 cells, displaying a chemotactic 
maximum of ∼10 nM, as compared with 5 nM for MIP-2 and KC, while no chemotaxis was observed 
in response to the control chemokine IP-10, a ligand for CXCR3 (Fig. 3⇓A), or by murine CXCR3-, 
CCR8-, or CCR6-transfected RBL-1 cells (data not shown). DCIP-1 also generated calcium flux (EC50 
75–100 nM) in K293/Gal6 and CHO/Gal6 CXCR2 transfectants (data not shown), and mediated 
potent recruitment of neutrophils, but not macrophages or mononuclear cells in vivo (Fig. 3⇓B). In 
addition to functioning as a ligand for murine CXCR2, DCIP-1 also mediated chemotaxis of human 
neutrophils with potency and efficacy equivalent to that of human IL-8 (Fig. 3⇓C).  
 
View larger version: 
FIGURE 3.  
DCIP-1 is a ligand for CXCR2 and mediates chemotaxis of neutrophils. A, Chemotaxis of murine 
CXCR2-transfected and untransfected RBL-1 cells in response to chemokines DCIP-1, KC, MIP-2, and 
IP-10. This is a representative experiment with each data point performed in duplicate. B, Peritoneal 
recruitment of macrophages, mononuclear cells, and neutrophils in response to DCIP-1 or MIP-2, 
represented as a percentage of recruitment in response to PBS alone (assigned as 100%). Data 
represents mean results obtained from five mice. C, Chemotaxis of human neutrophils in response 
to indicated concentrations of DCIP-1 or 10 nM human IL-8.  
DCIP-1 mRNA induction kinetics are consistent with an early proinflammatory function 
DCIP-1 mRNA levels increased rapidly, within 30 min of addition of LPS to BMDC cultures (Fig. 4⇓), 
consistent with an early role in establishing inflammation at sites of activation. MIP-2 mRNA peaked 
after ∼1 h, while DCIP-1 reached a maximum at ∼2–4 h. Both mRNAs decayed only very slowly to 
the 20 h time-point, compatible with the differential DCIP-1 expression detected by SAGE. RANTES 
(CCL5) and CCR7 transcript levels both increased less rapidly than DCIP-1 and MIP-2 and remained 
high to the 20-h time-point consistent with previous reports (10, 35).  
 
View larger version: 
FIGURE 4.  
Real-time PCR analysis of DCIP-1, MIP-2, RANTES, and CCR7 over a time-course of LPS-induced 
maturation of BMDCs. A single time-point at 20 h indicated no change in the levels of mRNA in the 
absence of LPS stimulation (not shown). This data is representative of at least three independently 
derived experiments. Error bars indicate the SD of PCR triplicates with data represented as the mean 
normalized ratio of the triplicates to HPRT.  
Induction of DCIP-1 mRNA is not restricted to BMDCs and is not prevented by pretreatment with 
IL-10 
Real-time PCR analysis confirmed SAGE data indicating that DCIP-1 mRNA is not expressed by Th1, 
Th2, or Treg clones (36) or by the fibroblast cell line NIH3T3. It further demonstrated that DCIP-1 is 
not expressed by the T cell line EL4 or the B cell lymphoma line A20, with or without PMA 
stimulation, the untreated B cell line CH27, or the macrophage cell line RAW, untreated or treated 
with LPS. Expression was not detected in muscle, kidney, brain, thymus, or skin (data not shown). 
DCIP-1 mRNA was, however, generated in response to LPS by primary macrophage populations, in 
particular by elicited peritoneal macrophages (Fig. 5⇓A). It was also generated by BMDCs in response 
to the alternative inflammatory stimulus, unmethylated CpG (Fig. 5⇓B). BMDCs pretreated with the 
anti-inflammatory cytokine IL-10 retained, and indeed appeared enhanced in their ability to 
generate DCIP-1 mRNA in response to LPS (Fig. 5⇓C). In each case, the relative expression of DCIP-1 
mRNA mirrored that of the related chemokine MIP-2 (Figs. 4⇑ and 5⇓).  
 
View larger version: 
FIGURE 5.  
DCIP-1 expression in BMDC and macrophage populations in response to inflammatory stimuli. 
Induction of DCIP-1 and MIP-2 mRNA assessed in, A, BMDCs, bone marrow, resident peritoneal and 
Biogel elicited peritoneal macrophages with (+) and without (−) the addition of 1 μg/ml LPS, and in B, 
BMDCs in response to LPS (1 μg/ml) and the alternative inflammatory, CpG (2 μM), or 
nonstimulatory GpC (2 μM), oligonucleotides, following 4 and 18 h exposure. Data is represented as 
the mean normalized ratio to HPRT, with error bars indicating the SD of PCR triplicates, and in each 
case is representative of at least two independent cell preparations. C, DCIP-1, MIP-2, and CCR7 
mRNA levels were assessed in 9 day BMDCs in response to LPS with and without preexposure to IL-
10. Values represent the mean normalized ratio to HPRT of two independently derived panels of 
cells analyzed in the same real-time PCR experiment, and is representative of at least three 
independent experiments. Error bars indicate the SD of six PCR.  
SAGE comparisons indicate that IL-10 conditions BMDC to an alternative state of activation 
IL-10 is generally considered to limit immune and inflammatory responses (37). While inclusion of IL-
10 in BMDC cultures does not impair phagocytic ability it does impair APC function (11), and BMDC 
treated with IL-10 were unable to acquire the ability to stimulate naive T cells in MLC, even following 
the addition of LPS (Fig. 6⇓A). The surface phenotype of IL-10-treated cells was reminiscent of 
untreated BMDCs, expressing moderate amounts of MHC II and CD86 and low levels of CD80, but in 
contrast to the untreated cells, these surface molecules were not up-regulated following exposure 
to LPS (Fig. 6⇓B). The effects of IL-10 were found to be time and concentration dependent, with 
maximal effects observed following culture with 20 ng/ml recombinant IL-10 for 72 h, with no 
adverse effect on cell viability observed by trypan blue exclusion (data not shown).  
 View larger version: 
FIGURE 6.  
Characterization of BMDCs conditioned by exposure to IL-10. A, Relative capacities of 9 day, 
untreated (○), IL-10-treated (▵), LPS-treated (▴), and IL-10-treated, LPS-treated (•) BMDCs to 
stimulate T cell proliferation, determined by allogeneic MLR. B, Surface phenotype of 9 day, 
untreated (filled histograms) and LPS-treated (open histograms) BMDCs, with and without exposure 
to IL-10, determined by flow cytometry. Broken lines represent background staining obtained using 
irrelevant species- and isotype-matched control Abs.  
Comparison of SAGE libraries generated from untreated (21,789 tags), LPS-treated (13,085 tags), IL-
10-conditioned (30,455 tags), and IL-10-conditioned, LPS-treated BMDCs (31,135 tags) (GEO, 
GSM3832–35), demonstrated marked global differences in gene expression. Although 58 genes were 
repressed or down-modulated in BMDCs following IL-10 treatment, 75 were up-regulated, of which 
9 were not represented in other immunologically related and unrelated libraries (GSM580, GSM367, 
GSM3677–87, and GSM3824–37). Of the overall changes seen in response to IL-10, 31 tags were in 
common with 73 changes seen in response to LPS alone (the number of statistically differential 
genes vary from those in Fig. 2⇑ due to the inclusion of larger numbers of libraries). Following LPS 
treatment of IL-10 conditioned cells, 41 of the 73 overall changes associated with maturation in 
response to LPS alone were still present, while 71 additional genes were statistically up- or down-
modulated.  
LPS-induction of CCR7, which was marked in response to LPS alone, and induction of tags associated 
with chemokines CCL17, CCL21, and CCL22s that promote various DC:T cell interactions, were 
hampered by IL-10 (Table I⇓ and Fig. 5⇑), indicating interference with mechanisms recruiting 
adaptive immunity, while the tag for programmed death ligand (PD-L)-1, involved in mediating the 
inability of IL-10 treated DCs to present Ag to T cells (38), was increased. In contrast, real-time PCR 
(Fig. 5⇑) indicated that IL-10 conditioning of BMDCs does not hinder LPS-induced expression of 
inflammatory molecules such as DCIP-1 and MIP-2, and SAGE tags for the genetically linked 
inflammatory chemokines CXCL4 and CXCL5, and the proinflammatory cytokine IL-1 were also 
increased (Table I⇓). Further, a decrease in tags for the decoy receptor molecule, IL-1R2, in response 
to IL-10 alone, indicated increased sensitivity to IL-1, although a counter increase in tags for the IL-1R 
antagonist was also apparent (39). An increase in tags for membrane-bound and soluble innate 
pattern recognition molecules, including macrophage receptor with collagenous structure (40), 
CD14, TLR2 (41), galectin-3 (42), and components of the alternative pathway of complement (43), in 
response to LPS, combined with a general increase in degrading lysosomal activity, suggest that in 
addition to promoting inflammation, exposure to IL-10 also promotes removal of pathogens via 
phagocytosis, consistent with observations of increased Ag uptake by IL-10-treated DCs in the 
presence of bacteria (11).  
View this table: 
Table I. 
Comparison of SAGE tag frequencies in immature and LPS-matured BMDC libraries following IL-10 
conditioning, normalized to per 104 tagsa 
Although IL-10-conditioned DCs retain and indeed appear enhanced in their capacity to generate at 
least a subset of proinflammatory mediators in response to LPS, a coordinated increase in the 
production of protective anti-inflammatory agents, such as heme oxygenase-1 (44), and arginase-1, 
which competes with inducible NO synthase for the shared substrate arginine, down-regulating 
synthesis of NO (45) (Table I⇑), is also seen. Inflammatory responses reflect a complex network of 
chemokine/protease interactions and the substantial increase in tags derived from lysosomal 
proteases, in particular cathepsins D, S, L, B, and C, following IL-10 treatment, could reflect 
alterations in this network, modifying subsequent cell recruitment and activation in response to 
inflammatory stimuli (46, 47, 48). IL-10 mediated unique acquisition of the SAGE tag for CXCL7 
(platelet basic protein), to a frequency of 64 per 104 (Table I⇑). Differential rates of processing of 
various inactive precursor forms of this chemokine result in pro- and anti-inflammatory effects, both 
mediated by neutrophil activating protein-2, with excessive accumulation of neutrophil activating 
protein-2 resulting in functional desensitization via down-regulation of CXCR2 (49). The 
accumulation of CXCL7 tags in response to IL-10 was reversed on subsequent addition of LPS (Table 
I⇑).  
Discussion 
We have described the identification and cloning of a novel CXC chemokine molecule, DCIP-1, using 
SAGE libraries derived from immature and LPS-matured BMDCs, and provide comparative SAGE and 
real-time PCR data indicating that the immune responsiveness of BMDCs is conditioned by IL-10 to 
promote local innate effector mechanisms, while inductive mechanisms capable of recruiting 
adaptive immunity are down-graded.  
DCIP-1 is an ELR+, CXC chemokine which, by homology, belongs to the subgroup of proinflammatory, 
neutrophil-attracting chemokines comprising murine MIP-2, KC, rat CINC, and the human GRO 
proteins, and would appear to represent the murine homologue of rat CINC2. It functions as a ligand 
for CXCR2 mediating selective recruitment of murine neutrophils in vivo, and can also cross species 
to mediate chemotaxis of human neutrophils in vitro (Fig. 3⇑). The kinetics of DCIP-1 mRNA 
induction in response to LPS are consistent with a role for this novel chemokine during the early 
proinflammatory phase of DC maturation (Fig. 4⇑).  
DCs not only initiate immune responses, but also determine whether they are driven toward 
appropriately skewed immunity, or alternatively toward unresponsiveness or tolerance (1, 2, 3, 4). 
IL-10 is among a number of agents reported to modulate DCs for the generation of Ag specific 
anergy (5, 6, 7, 8), and it has been variously considered that it may be acting either by inhibiting 
normal maturation (7, 11), or by conditioning DCs to acquire an alternative activation state (13). 
From a global perspective, the changes in gene expression observed by comparative SAGE analysis 
are supportive of a mechanism more subtle than simple inhibition of maturation. As a consequence 
of IL-10 treatment, 31 tags varied in common with changes seen in the response of BMDCs to LPS, 
suggesting at least some form of partial activation, although 102 tags were also modulated 
independently. Following LPS treatment of these cells, while 41 of 73 changes associated with LPS 
maturation in the absence of IL-10 were retained, again suggesting that aspects of the normal 
response to LPS have been preserved, 71 additional tags were modulated. These changes are 
persuasive that IL-10 actively drives DCs to acquire a modified state from which to respond to 
inflammatory stimuli.  
IL-10 has no effect on the ability of BMDCs to pick up and process Ag (11), a classic function of 
immature DCs, but prevents them from acquiring the ability to effectively present this Ag to naive T 
cells, a feature which has been attributed to failure to up-regulate MHC class II and costimulatory 
molecules (7, 11) (Fig. 6⇑). An important contribution to this IL-10-mediated decrease in stimulatory 
capacity is provided by the interaction of PD-L1 and PD-L2 with their receptor programmed death 
receptor-1 (38), and is reflected in the SAGE data (Table I⇑). Although a fragment of Ii-p41 has been 
shown to inhibit the Ii processing enzyme cathepsin L (50), the impact of a 3.3-fold increase in CD74 
in response to IL-10, which is reversed on subsequent exposure to LPS, (Table I⇑), is uncertain. 
Despite an increase in cathepsin S and L SAGE tags in response to IL-10 (Table I⇑), lysosomal 
acidification, rather than changes in individual protease levels, is considered to be the critical 
determinant controlling transport of peptide:MHC class II complexes to the cell surface (26, 51). In 
contrast to MHC II, tags for MHC class I and β-2M were elevated in response to IL-10, and on 
addition of LPS attained levels equivalent to those generated by LPS alone, consistent with surface 
expression data (Table I⇑ and Fig. 6⇑).  
IL-10 blocks the maturation-induced switch from inflammatory chemokine receptors, such as CCR1 
and CCR5, to the lymphoid homing receptor CCR7, inhibiting migration to the lymph nodes and 
recruitment of T cells (12, 52). This block in CCR7 induction was apparent by SAGE, which also 
indicated a similar block in induction of the T cell attracting chemokines CCL17, CCL21, and CCL22 
(Table I⇑). The slight increase in CCR7 expression revealed by real-time PCR, was also apparent in 
previous reports, but did not prevent the inhibitory effect of IL-10 on migration (12, 52). CCR1 and 
CCR5 tag levels were not reduced following IL-10 conditioning (Table I⇑). These receptors remain at 
the cell surface, but are functionally uncoupled (12), acting as scavengers to reduce local ligand 
levels, an effect reinforced by reduction in LPS-induced synthesis of ligands, such as CCL3 and CCL4 
(12), which are also substrates for the elevated protease cathepsin D (48), and CCL5 (Table I⇑).  
In contrast to the down-regulation of CC inflammatory chemokines that mediate recruitment of 
immature DCs and also activated T cells to sites of inflammation, IL-10 conditioning of BMDC does 
not impair LPS-induced synthesis of neutrophil attracting CXC inflammatory chemokines, such as 
DCIP-1 and MIP-2, or the proinflammatory cytokine IL-1 (Fig. 5⇑ and Table I⇑). These data contrast 
with previous reports of the anti-inflammatory effect of IL-10 in in vivo models (37, 53, 54), and 
probably reflect the critical importance of context in cytokine behavior. Indeed, the effects of IL-10 
in vivo, and on individual cell types, are not always anti-inflammatory (55, 56, 57). Down-modulation 
of the IL-1R2 decoy receptor in response to IL-10 is suggestive of priming for IL-1 responsiveness, 
while the general increase in degrading lysosomal activity, in association with LPS-induced 
expression of membrane bound and soluble pattern recognition molecules, is indicative of enhanced 
phagocytic bacterial clearance (Table I⇑). The increase in inflammatory potential following exposure 
to IL-10 appears to be tempered by a coordinated increase in the production of anti-inflammatory 
agents, such as heme oxygenase-1, reportedly responsible for IL-10-mediated protection of mice 
from LPS-induced septic shock (44), arginase-1, IL-1R antagonist, and potentially CXCL7 (Table I⇑) 
(39, 45, 49).  
It would appear that while classic maturation of BMDCs indeed does not occur in response to 
bacterial stimuli following pretreatment with IL-10, this is not simply due to a block in maturation, 
since aspects of the “normal” response are retained. The IL-10-treated cells described here are 
phenotypically distinct from the “semi-mature” DCs implicated in maintaining peripheral tolerance 
(58), but they could also be regarded as a type of “semi-mature” cell, in which the ability to activate 
and recruit T cells in response to LPS-signaling is constrained, while the ability to promote local 
inflammation and bacterial clearance is enhanced. How these observations relate to particular 
subsets of DCs and biological scenarios in vivo remains to be established. However, if the full clinical 
potential of future DC-based therapeutics is to be realized (5, 59), it will also be important to 
appreciate the complete immune-responsive spectrum of ex vivo manipulated populations. SAGE 
provides a versatile approach to characterizing these cells, providing both for the identification of 
novel molecules, potentially representing new therapeutic targets in their own right, and as an 
indicator of key changes in cellular processes.  
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